Quick Search 
Drugs of the Future
Register or sign in

  
 
  
Drugs Fut 2012, 37(6): 451
ISSN 0377-8282
Copyright 2012 Clarivate Analytics
CCC: 0377-8282
DOI: 10.1358/dof.2012.037.06.1820866
 
 
American Association for Cancer Research (AACR) - 103rd Annual Meeting, Chicago, Illinois, USA - March 31 - April 4, 2012
Macauley, D., Fernandez, R., Colombo, A.
 
 
The 103rd Annual Meeting of the American Association for Cancer Research (AACR), held in Chicago, Illinois, included presentations and symposia designed to bring together experts in the field to discuss the progress in cancer research. A number of different topics were discussed, including the development of therapeutics for the control of metabolic pathways, the role of microRNAs in the treatment of cancer and the potential for individualizing cancer prevention. This report highlights selected presentations from a session on new drugs on the horizon. Investigational drugs discussed included BYL-719 (Novartis), GSK-2636771 (GSK-2636771B and GSK-2636771A; GlaxoSmithKline), MLN-2480 (BIIB-024; Millennium Pharmaceuticals/Sunesis Pharmaceuticals), ABT-199 (GDC-0199, RG-7601; Abbott Laboratories/Genentech) and SAR-29915 (Sanofi).


Full Text: PDF 
 
  



© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy